LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

Search

Corcept Therapeutics Inc

Gesloten

SectorGezondheidszorg

79.62 6.37

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

74.39

Max

79.72

Belangrijke statistieken

By Trading Economics

Inkomsten

15M

35M

Verkoop

37M

194M

K/W

Sectorgemiddelde

64.981

35.293

EPS

0.169

Winstmarge

18.078

Werknemers

500

EBITDA

23M

27M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+89.64% upside

Dividenden

By Dow Jones

Volgende Winsten

29 okt 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

345M

7.7B

Vorige openingsprijs

73.25

Vorige sluitingsprijs

79.62

Nieuwssentiment

By Acuity

20%

80%

30 / 371 Rangschikking in Healthcare

Corcept Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

18 sep 2025, 23:56 UTC

Populaire aandelen

Stocks to Watch: FedEx, 22nd Century, Scholastic

18 sep 2025, 22:01 UTC

Belangrijke Marktbewegers

22nd Century Group Shares Gain on Debt Repayment, New Capital

18 sep 2025, 20:51 UTC

Acquisities, Fusies, Overnames

UPS Terminates Plan to Buy Estafeta

18 sep 2025, 20:31 UTC

Winsten

FedEx 1Q Profit, Sales Rise on Improvement in U.S. Shipping -- Update

18 sep 2025, 20:26 UTC

Winsten

FedEx 1Q Profit, Sales Rise on Improvement in U.S. Shipping

18 sep 2025, 23:43 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

18 sep 2025, 23:43 UTC

Marktinformatie

Nikkei May Rise on U.S. Stock Gains, Weaker Yen -- Market Talk

18 sep 2025, 23:43 UTC

Marktinformatie

Global Equities Roundup: Market Talk

18 sep 2025, 23:40 UTC

Marktinformatie

Gold Edges Lower Amid Cautious Mood -- Market Talk

18 sep 2025, 23:31 UTC

Marktinformatie

FedEx Says U.S. Demand Is Resilient -- Market Talk

18 sep 2025, 22:03 UTC

Winsten

FedEx Expects Trade Environment to Create $1B Headwind in 2026, CFO Says

18 sep 2025, 22:01 UTC

Winsten

FedEx CFO: Asia-to-U.S. Declines Drove $150M International Export Headwind

18 sep 2025, 21:56 UTC

Winsten

Lennar Missed Revenue Estimates. The Stock Is Down. -- Barrons.com

18 sep 2025, 21:54 UTC

Winsten

FedEx Focused on Demand From Southeast Asia, Europe Amid China Shipping Slowdown, Customer Chief Says

18 sep 2025, 21:48 UTC

Winsten

FedEx International Export Volumes Declined, Especially on China-to-U.S. Lane, Exec Says

18 sep 2025, 21:47 UTC

Winsten

FedEx Had 5% Increase in U.S. Domestic Average Daily Package Volume in 1Q, Customer Chief Says

18 sep 2025, 21:17 UTC

Winsten

FedEx Profit, Sales Rise on Improvement in U.S. Shipping -- 2nd Update

18 sep 2025, 21:07 UTC

Winsten

FedEx Earnings Were a Relief. The Stock Is Up. -- Barrons.com

18 sep 2025, 20:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

18 sep 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

18 sep 2025, 20:50 UTC

Marktinformatie
Winsten

Financial Services Roundup: Market Talk

18 sep 2025, 20:50 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

18 sep 2025, 20:22 UTC

Acquisities, Fusies, Overnames

UPS Cites Inability of All Closing Conditions to Be Satisfied

18 sep 2025, 20:22 UTC

Acquisities, Fusies, Overnames

United Parcel Service Terminates Plan to Buy Estafeta

18 sep 2025, 20:20 UTC

Acquisities, Fusies, Overnames

Here's How Much the U.S. Has Made on Its Intel Stock Purchase -- Barrons.com

18 sep 2025, 20:18 UTC

Winsten

Nucor Stock Falls After Earnings. Why Its Guidance Was Far Off Rival Steel Dynamics. -- Barrons.com

18 sep 2025, 20:18 UTC

Winsten

Bullish Crushes Earnings. The Crypto Stock Pops. -- Barrons.com

18 sep 2025, 20:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

18 sep 2025, 20:07 UTC

Winsten

FedEx Earnings Were a Relief. The Stock Is Up. -- Barrons.com

18 sep 2025, 20:03 UTC

Winsten

FedEx 1Q FedEx Freight Segment Revenue $2.26B >FDX

Peer Vergelijking

Prijswijziging

Corcept Therapeutics Inc Prognose

Koersdoel

By TipRanks

89.64% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 135.25 USD  89.64%

Hoogste 145 USD

Laagste 121 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corcept Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Sentiment

By Acuity

30 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
help-icon Live chat